NEO212

Nov. 2, 2026: NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) said it will present two posters at the Society for Neuro-Oncology 31st Annual Meeting (Nov. 12-15, 2026, Philadelphia), with both presentations scheduled for Nov. 13, 2026.

NEO100: Updated Phase 1/2a and compassionate-use data for intranasal NEO100 will be presented in recurrent WHO grade III/IV IDH1-mutant astrocytoma. The poster title indicates durable radiographic remission and prolonged survival; no numerical results were provided in the release. NEO100 is a highly purified perillyl alcohol administered intranasally and remains investigational.

NEO212: Phase 1 data for oral NEO212 will be presented in TMZ-resistant recurrent glioblastoma and brain metastases, covering safety, pharmacokinetics, and early signals of activity. The release states NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NEO212 is an investigational oral conjugate of temozolomide and NEO100 being developed under an FDA investigational new drug application.

Catalyst: conference data presentation at SNO on Nov. 13, 2026; no regulatory decisions or detailed efficacy/safety data were disclosed in the release.